Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan.
Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan.
复制标题
DOI：
10.1007/s10157-021-02157-x
复制
发表时间：
2022-04
影响因子：
2.3
通讯作者：
Suzuki Y
中科院分区：
文献类型：
--
作者：
Matsuzaki K;Aoki R;Nihei Y;Suzuki H;Kihara M;Yokoo T;Kashihara N;Narita I;Suzuki Y
最近的临床报告表明，肾小球肾炎患者，特别是免疫球蛋白 A 肾病 (IgAN) 患者接种 2019 冠状病毒 (COVID-19) 疫苗后出现的肉眼血尿之间存在相关性。此外，日本的医护人员从2021年2月17日起首次接种了mRNA疫苗，其中一些人在接种疫苗后出现了肉眼血尿。我们对日本肾病学会委员（581 名会员、382 个机构）进行了一项网络调查，以阐明肉眼血尿与 COVID-19 疫苗接种之间的关系。在第一项调查中，有 27 例（女性：22 例，81.5%）在接种 COVID-19 疫苗后出现肉眼血尿。其中，19名（70.4%）患者在出现肉眼血尿时已被诊断为IgAN。接种前无蛋白尿的14例中有8例（57.1%）出现蛋白尿，接种前无血尿的7例中有5例（71.4%）出现血尿。第二次调查显示，有 4 例疫苗接种后进行了肾活检，全部被诊断为 IgAN。仅1例出现血清肌酐水平轻度升高，无患者进展为严重肾功能不全。这项研究阐明了接种 COVID-19 疫苗后出现肉眼血尿的临床特征。由于没有明显进展为严重肾功能障碍，因此至少在两次接种方案中保证了 COVID-19 疫苗接种的安全性。在线版本包含可在 10.1007/s10157-021-02157-x 获取的补充材料。
Recent clinical reports indicate a correlation between gross hematuria after the coronavirus 2019 (COVID-19) vaccination in patients with glomerulonephritis, especially immunoglobulin A nephropathy (IgAN). Furthermore, healthcare workers in Japan were initially vaccinated with an mRNA vaccine from February 17, 2021, and some of them experienced gross hematuria after receiving the vaccination. We conducted a web-based survey of the councilor members of the Japanese Society of Nephrology (581 members, 382 facilities) to elucidate the relationship between gross hematuria and COVID-19 vaccination. In the first survey, 27 cases (female: 22, 81.5%) of gross hematuria were reported after receiving a COVID-19 vaccination. Of them, 19 (70.4%) patients were already diagnosed with IgAN at the occurrence of gross hematuria. Proteinuria appeared in eight of the 14 (57.1%) cases with no proteinuria before vaccination and hematuria in five of the seven (71.4%) cases with no hematuria before vaccination. The second survey revealed that a renal biopsy was performed after vaccination in four cases, all of whom were diagnosed with IgAN. Only one case showed a slightly increased serum creatinine level, and no patients progressed to severe renal dysfunction. This study clarified the clinical features of gross hematuria after a COVID-19 vaccination. Because there was no obvious progression to severe renal dysfunction, safety of the COVID-19 vaccination is warranted at least in the protocol of inoculation twice. The online version contains supplementary material available at 10.1007/s10157-021-02157-x.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2101544
发表时间：
2021-06-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Sadoff J;Gray G;Vandebosch A;Cárdenas V;Shukarev G;Grinsztejn B;Goepfert PA;Truyers C;Fennema H;Spiessens B;Offergeld K;Scheper G;Taylor KL;Robb ML;Treanor J;Barouch DH;Stoddard J;Ryser MF;Marovich MA;Neuzil KM;Corey L;Cauwenberghs N;Tanner T;Hardt K;Ruiz-Guiñazú J;Le Gars M;Schuitemaker H;Van Hoof J;Struyf F;Douoguih M;ENSEMBLE Study Group
通讯作者：
ENSEMBLE Study Group
DOI：
10.1016/s0140-6736(20)31605-6
发表时间：
2020-08-15
期刊：
Lancet (London, England)
影响因子：
--
作者：
Zhu FC;Guan XH;Li YH;Huang JY;Jiang T;Hou LH;Li JX;Yang BF;Wang L;Wang WJ;Wu SP;Wang Z;Wu XH;Xu JJ;Zhang Z;Jia SY;Wang BS;Hu Y;Liu JJ;Zhang J;Qian XA;Li Q;Pan HX;Jiang HD;Deng P;Gou JB;Wang XW;Wang XH;Chen W
通讯作者：
Chen W
影响因子：
13.6
作者：
Suzuki, Hitoshi;Suzuki, Yusuke;Tomino, Yasuhiko
通讯作者：
Tomino, Yasuhiko